

Haematologica
HAEMATOL/2020/256453
Version 4

Impact of luteinizing hormone suppression on hematopoietic recovery
after intensive chemotherapy in patients with leukemia

Iman Abou Dalle, Ronald Paranal, Jabra Zarka, Shilpa Paul, Koji Sasaki, Wen Li, Jing Ning, Nicholas J. Short, Maro Ohanain, Jorge E. Cortes, Elias J. Jabbour, and Ghayas C. Issa

Disclosures: NJS received research funding from Takeda Oncology, consultancy fees from AstraZeneca, Takeda Oncology and Amgen. JEC received research funding from Ambit BioSciences, ARIAD, Arog, Astellas Pharma, AstraZeneca, Bristol-Myers Squibb, Celator, Celgene, Novartis, Pfizer, Sanofi, Sun Pharma, Teva; consultant fees from Ambit BioSciences, ARIAD, Astellas Pharma, BiolineRx, Bristol-Myers Squibb, Novartis; Pfizer. EJJ received research funding and consultancy fees from Takeda, BMS, Adaptive, Amgen, AbbVie, Pfizer and Cyclacel LTD. GCI received research funding from Celgene, Syndax and Novartis and served on an advisory board for Novartis.

Contributions: IA wrote the manuscript. IA, RMP, JZ, SP, KS, NJS, MO, JEC, EJJ contributed to data collection and analysis. WL and JN analyzed the data and performed the statistical analysis. GCI designed the study, supervised the analysis and wrote the manuscript.